FIELD: medicine, pharmaceutics.
SUBSTANCE: pyrazolo[1,5-a]-pyrimidine compounds according to the invention are specified in a group consisting of: N-{2-fluor-5-[3-nitro-pyrazolo[1,5-a]pyrimidin-7-yl]-phenyl}-N-methylacetamide, N-{2-fluor-5-[3-cyano-pyrazolo[1,5-a]pyrimidin-7-yl]-phenyl}-N-methylacetamide, N-{2-chlor-5-[3-nitro-pyrazolo[1,5-a]pyrimidin-7-yl]-phenyl}-N-methylacetamide, N-{2-chlor-5-[3-cyano-pyrazolo[1,5-a]pyrimidin-7-yl]-phenyl}-N-methylacetamide, N-{2-fluor-5-[3-nitro-pyrazolo[1,5-a]pyrimidin-7-yl]-phenyl}-N-ethylmethanesulphonamide; {2-fluor-5-[3-cyano-pyrazolo[1,5-a]pyrimidin-7-yl]-phenyl}-N-methylmethanesulphonamide, N-{2-chlor-5-[3-nitro-pyrazolo[1,5-a]pyrimidin-7-yl]-phenyl}-N-methylmethanesulphonamide, N-{2-chlor-5-[3-cyano-pyrazolo[1,5-a]pyrimidin-7-yl]-phenyl}-N-methylmethanesulphonamide, N-{2-fluor-5-[3-cyano-2-methyl-pyrazolo[1,5-a]pyrimidin-7-yl]-phenyl}-N-methylacetamide, N-{2-chlor-5-[3-cyano-2-methyl-pyrazolo[1,5-a]pyrimidin-7-yl]-phenyl}-N-methylacetamide, N-{2-fluor-5-[3-cyano-2-methyl-pyrazolo[1,5-a]pyrimidin-7-yl]-phenyl}-N-methyl-methanesulphonamide, N-{2-chlor-5-[3-cyano-2-methyl-pyrazolo[1,5-a]pyrimidin-7-yl]-phenyl}-N-methyl-methanesulphonamide, N-{2-methyl-5-[3-(thiophene-2-carbonyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-phenyl}-N-methylacetamide, N-{2-methoxy-5-[3-(thiophene-2-carbonyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-phenyl}-N-methylacetamide, N-{2,4-difluor-5-[3-(thiophene_2-carbonyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-phenyl}-N-methylacetamide and N-{5-fluor-2-methoxy-3-[3-(thiophene-2-carbonyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-phenyl}-N-methylacetamide.
EFFECT: preparing pyrazolo[1,5-a]pyrimidine compounds, their pharmaceutically acceptable salts and hydrates showing an ability to inhibit GABAA receptors, and applicable for treating and preventing anxiety, epilepsy and sleeping disorders, including insomnia, as well as for inducing a sedative-hypnotic, analgesic and sleeping effects and myorelaxation.
14 cl, 6 tbl, 4 dwg, 22 ex
Title | Year | Author | Number |
---|---|---|---|
HALOGENISED PYRAZOLO[1,5-a]PYRIMIDINES (VERSIONS), METHODS FOR PREPARING THEM, BASED PHARMACEUTICAL COMPOSITION, INTERMEDIATE COMPOUNDS AND METHOD FOR PREPARING THEM (VERSIONS) | 2006 |
|
RU2478101C2 |
TRIAZOLE DERIVATIVES AS GABA RECEPTOR LIGANDS | 2011 |
|
RU2582337C2 |
NOVEL LIGANDS OF ESTROGEN RECEPTORS | 2009 |
|
RU2492164C2 |
AMINOPYRAZOLOPYRIMIDINE COMPOUND USED AS INHIBITOR OF TYROSINE KINASE RECEPTOR OF NEUROTROPHIC FACTOR | 2017 |
|
RU2764523C2 |
THIAZOLOPYRIMIDINONES AS MODULATORS OF NMDA RECEPTOR ACTIVITY | 2014 |
|
RU2703273C2 |
2,6-SUBSTUTED-4-MONOSUBSTITUTED AMINO-PYRIMIDINES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | 2005 |
|
RU2417990C2 |
NEW PYRIMIDINE DERIVATIVE WITH AN EFFECT OF INHIBITING GROWTH OF CANCER CELLS AND PHARMACEUTICAL COMPOSITION CONTAINING IT | 2018 |
|
RU2744168C1 |
ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF FOR INHIBITING NOREPINEPHRINE, DOPAMINE AND SEROTONIN REUPTAKE | 2005 |
|
RU2388751C2 |
NOVEL 1,2-BIS-SULPHONAMIDE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR | 2011 |
|
RU2654213C9 |
AMINOPYRIMIDINE DERIVATIVES AND USE THEREOF AS AROMATIC HYDROCARBON RECEPTOR MODULATORS | 2021 |
|
RU2826628C1 |
Authors
Dates
2012-08-10—Published
2007-08-02—Filed